PT  - JOURNAL ARTICLE
AU  - Gadducci, Angiolo
AU  - Katsaros, Dionyssios
AU  - Zola, Paolo
AU  - Scambia, Giovanni
AU  - Ballardini, Michela
AU  - Pasquini, Enzo
AU  - Fertonani, Carlo
AU  - Maggi, Lorenzo
AU  - Pecorelli, Sergio
AU  - Conte, Pier Franco
AU - other members of the After-6 Italian Cooperative Group
TI  - Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy: Results of an Open Noncomparative Phase 2 Multicenter Italian Study (After-6 Protocol 2)
AID  - 10.1111/IGC.0b013e3181a4476b
DP  - 2009 Apr 01
TA  - International Journal of Gynecologic Cancer
PG  - 615-619--615-619
VI  - 19
IP  - 4
4099  - http://ijgc.bmj.com/content/19/4/615-619.short
4100  - http://ijgc.bmj.com/content/19/4/615-619.full
SO  - Int J Gynecol Cancer2009 Apr 01; 19
AB  - The aim of this paper was to assess whether weekly intravenous 60-mg/m2 paclitaxel for 21 weeks is feasible and effective as maintenance treatment in 64 patients with advanced ovarian cancer who had microscopic residual disease after 6 cycles of paclitaxel/platinum-based chemotherapy. Forty-eight patients completed the planned cycles of weekly paclitaxel. The worst toxicities were grade 2 leukopenia in 22.4% of the patients, grade 2 neutropenia in 25.9%, grade 2 sensorial neurotoxicity in 20.7%, and grade 2 motor neurotoxicity in 6.9%. Seventeen patients underwent a third-look surgery that showed a pathological complete response in 6 (35.3%, 95% confidence interval [CI], 17.3%-59.0%) cases. The 3-year progression-free survival rate was 18% (95% CI, 9.6%-33.8%), and the 3-year overall survival rate was 64% (95% CI, 52.0%-78.0%). Weekly low-dose paclitaxel is a feasible and well-tolerated maintenance treatment.